All In Biotech

Drug Trial Radar · NCT07868328

A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Tauopathies

A Phase II, Randomized, Double Blind, Placebo-controlled, Basket Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Participants With Primary Tauopathies

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Oct 23, 2026

Primary completion

Mar 26, 2029

Study completion May 20, 2030

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Oct 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 41 years, up to 81 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase II study intended to evaluate the safety, tolerability and pharmacodynamics of NIO752 in participants with primary tauopathies. Eligible participants will be randomized to receive either NIO752 or placebo during the double-blind treatment period followed by an Open-label Extension (OLE).

Conditions

  • Progressive Supranuclear Palsy
  • Corticobasal Degeneration
  • Frontotemporal Lobar Degeneration
  • Tauopathies

Interventions

  • NIO752Drug

    Antisense Oligonucleotide Solution

  • PlaceboDrug

    Placebo solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) in double blind periodTime frame: From first treatment administration up to week 48

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.